Calcitonin intranasal (Salmocalcin) - sanofi-aventis

Drug Profile

Calcitonin intranasal (Salmocalcin) - sanofi-aventis

Alternative Names: Salcatonin intranasal - Sanofi-Aventis; Salmocalcin Nasal

Latest Information Update: 01 Aug 2012

Price : $50

At a glance

  • Originator Sanofi Winthrop
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypercalcaemia; Osteitis deformans; Postmenopausal osteoporosis

Most Recent Events

  • 20 Jul 2012 The European Medicines Agency recommended that intranasal calcitonin-containing medicines should not be used for osteoporosis. Due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .
  • 27 Aug 2004 Sanofi-Synthélabo has merged with Aventis to form Sanofi-Aventis.
  • 27 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top